NovaGo Therapeutics raised €8.9M in a Series A round in Jan 2019. The company is based in Schlieren, Switzerland. Investors in the round: Neurimmune Holding, Pureos Bioventures. Data as of 7 Aug 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
This is the company's only recorded round.
